Trial Profile
Observational National Clinical Trial of Safety and Tolerance in Patients Suffering of an Allergic Grass Pollen Rhinitis and Treated by Grazax in Real Life Settings
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 01 Apr 2022
Price :
$35
*
At a glance
- Drugs Timothy grass pollen allergen extract (Grastek) (Primary)
- Indications Allergic rhinitis; Grass pollen hypersensitivity
- Focus Adverse reactions; Therapeutic Use
- Acronyms GRAAL
- Sponsors ALK-Abello
- 16 Sep 2011 ClinicalTrials.gov record identified as an additional source, and actual patient numbers, lead investigator, and ALK Abello A/S added
- 16 Sep 2011 Status changed from recruiting to completed, as reported in the NCT record
- 27 Jun 2011 New trial record